Pembrolizumab,Cisplatin,Gemcitabine,Pemetrexed
merck
['key,note,62', 'keynote,671', 'keynote-671', 'key,note,24']
efficacy primary endpoints
keynote-671 #asco23 efs: nr vs 17mo hr 0.58 24mo efs: 62.4% vs 40.6% os immature 
MD, PhD - Thoracic Oncologist. Precision Medicine Consultant & Co-Founder PxMedica and Medical Consultant @bradfordhill_cl.